Repligen

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Repligen and other ETFs, options, and stocks.

About RGEN

Repligen Corp. is a global life sciences company, which engages in providing bioprocessing technologies and solutions used in the process of manufacturing biological drugs. It operates through the North America. 

CEO
Olivier Dominique Loeillot
CEOOlivier Dominique Loeillot
Employees
1,778
Employees1,778
Headquarters
Waltham, Massachusetts
HeadquartersWaltham, Massachusetts
Founded
1981
Founded1981
Employees
1,778
Employees1,778

RGEN Key Statistics

Market cap
8.04B
Market cap8.04B
Price-Earnings ratio
5.64K
Price-Earnings ratio5.64K
Dividend yield
Dividend yield
Average volume
983.16K
Average volume983.16K
High today
$144.64
High today$144.64
Low today
$139.46
Low today$139.46
Open price
$143.12
Open price$143.12
Volume
623.85K
Volume623.85K
52 Week high
$182.52
52 Week high$182.52
52 Week low
$102.97
52 Week low$102.97

Stock Snapshot

As of today, Repligen(RGEN) shares are valued at $142.82. The company's market cap stands at 8.04B, with a P/E ratio of 5641.25.

As of 2025-11-08, Repligen(RGEN) stock has fluctuated between $139.46 and $144.64. The current price stands at $142.82, placing the stock +2.4% above today's low and -1.3% off the high.

The Repligen(RGEN)'s current trading volume is 623.85K, compared to an average daily volume of 983.16K.

During the past year, Repligen(RGEN) stock moved between $102.97 at its lowest and $182.52 at its peak.

During the past year, Repligen(RGEN) stock moved between $102.97 at its lowest and $182.52 at its peak.

RGEN News

Simply Wall St 2d
Repligen: $48.1 Million One-Off Loss Raises Questions Despite Forecasted Earnings Surge

Repligen (RGEN) is back in focus after reporting a one-off net loss of $48.1 million for the twelve months ending September 30, 2025. Despite this significant c...

Repligen: $48.1 Million One-Off Loss Raises Questions Despite Forecasted Earnings Surge
Simply Wall St 5d
Is Repligen’s Upbeat 2025 Outlook a Sign of Sustainable Competitive Strength?

Repligen Corporation recently announced its third quarter 2025 earnings, reporting revenue of US$188.81 million and net income of US$14.91 million, both marking...

Is Repligen’s Upbeat 2025 Outlook a Sign of Sustainable Competitive Strength?
Simply Wall St 6d
Repligen: Assessing Valuation After Q3 Revenue Beat and Lower Profit Guidance

Repligen (RGEN) delivered third-quarter results that grabbed investor attention, with revenues jumping well ahead of forecasts thanks to double-digit growth acr...

Repligen: Assessing Valuation After Q3 Revenue Beat and Lower Profit Guidance

Analyst ratings

83%

of 23 ratings
Buy
82.6%
Hold
17.4%
Sell
0%

People also own

Based on the portfolios of people who own RGEN. This list is generated using Robinhood data, and it’s not a recommendation.
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.